What is Cardiovascular Disease?
Kardiyovasküler hastalıklar dünya genelinde ölüm nedenlerinin başında gelmektedir. Geleneksel tedaviler semptomları yönetmeye ve daha fazla hasarı önlemeye odaklanırken, rejeneratif tıp yaklaşımları devrimci bir yaklaşım sunar: hasarlı kalp dokusunu gerçekten yenilemek.
Göbek kordonundan elde edilen mezenkimal kök hücreler (MSC'ler), kardiyak rejenerasyonda dikkat çekici bir potansiyel göstermiştir. Bu hücreler kardiyomiyositlere (kalp kası hücreleri) dönüşebilir, yeni kan damarlarının oluşumunu destekleyebilir ve kalp hastalığı ilerlemesine katkıda bulunan iltihabı azaltabilir.
StemCell Longevita'da, durumunuza ve ihtiyaçlarınıza bağlı olarak kök hücreleri doğrudan kalbe veya intravenöz infüzyon yoluyla iletmek için son teknoloji protokoller kullanıyoruz.
Benefits of Regenerative Approach for Heart Disease
Clinical research has demonstrated significant potential for MSC therapy in addressing cardiovascular disease, promoting cardiac repair and functional improvement.
How Stem Cells Work for Cardiovascular Disease
MSC therapy for cardiovascular conditions targets the damaged heart tissue and impaired vasculature through multiple regenerative pathways. Clinical studies suggest that MSCs can promote cardiac repair, stimulate new blood vessel growth, and reduce the fibrosis and inflammation that compromise heart function.
MSCs release paracrine factors including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and angiopoietin-1 that stimulate angiogenesis — the formation of new blood vessels. This neovascularization improves blood supply to ischemic heart tissue, restoring oxygen and nutrient delivery to areas damaged by coronary artery disease or heart attack.
Following myocardial infarction, scar tissue (fibrosis) replaces functional heart muscle, reducing cardiac output. MSCs secrete anti-fibrotic factors including matrix metalloproteinases (MMPs) and hepatocyte growth factor (HGF) that can remodel scar tissue and reduce fibrosis, potentially improving the contractile function of the damaged ventricle.
MSCs release potent anti-inflammatory cytokines that reduce chronic cardiac inflammation, a major contributor to progressive heart failure. By suppressing pro-inflammatory pathways and promoting resolution of inflammation, MSCs help create an environment conducive to cardiac tissue healing and functional recovery.
Clinical research indicates that MSCs secrete cardioprotective factors that support the survival of existing cardiomyocytes (heart muscle cells) and may stimulate the activation of resident cardiac progenitor cells. This combined effect helps preserve and potentially restore cardiac function following ischemic injury.
Who Is a Good Candidate?
Candidacy for cardiovascular the regenerative approach is determined through comprehensive cardiac evaluation, including echocardiography, cardiac biomarkers, stress testing, and imaging studies. Our cardiologists assess each patient to ensure treatment suitability and safety.
Ideal Candidates
- Patients with chronic heart failure (NYHA Class II-III) who remain symptomatic despite optimal medical therapy including ACE inhibitors, beta-blockers, and diuretics
- Individuals with ischemic cardiomyopathy and reduced left ventricular ejection fraction (LVEF below 40%) who are not candidates for or prefer alternatives to surgical intervention
- Post-myocardial infarction patients with residual cardiac dysfunction seeking to improve functional capacity and quality of life beyond standard rehabilitation
- Patients with stable coronary artery disease experiencing persistent angina or exercise intolerance despite revascularization procedures
- Individuals with early-stage dilated cardiomyopathy seeking proactive regenerative treatment to slow disease progression
May Not Be Suitable
- Patients with decompensated heart failure requiring acute hemodynamic stabilization, mechanical circulatory support, or urgent transplant evaluation
- Individuals with active myocarditis, endocarditis, or other acute cardiac infections that must be resolved before regenerative treatment
- Patients with severe, uncontrolled arrhythmias or those with implanted devices that may interfere with treatment protocols
- Individuals with active malignancy or those undergoing chemotherapy or radiation therapy that could compromise stem cell function
What Results Can You Expect?
Recovery and improvement timelines for cardiovascular regenerative medicine approach vary based on the type and severity of heart disease, baseline cardiac function, and overall health. The following represents a general guide based on clinical trial data and patient outcomes.
Initial Recovery
The intravenous infusion is well-tolerated with minimal recovery time. Patients may be monitored for cardiac rhythm stability. Most patients resume normal activities within a few days of treatment.
Early Improvements
Many patients report improved energy levels and reduced shortness of breath during daily activities. Early improvements in exercise tolerance and overall stamina are commonly observed during this period.
Progressive Results
Measurable improvements in cardiac function may begin to appear on follow-up echocardiography, including improvements in ejection fraction. Patients often report significant reductions in fatigue and improved functional capacity.
Optimal Results
Peak therapeutic benefits are typically achieved, with clinical studies reporting improvements in LVEF, reduced cardiac fibrosis markers, and enhanced quality of life scores compared to baseline.
Long-Term Benefits
Sustained cardiovascular improvements may continue as new blood vessel networks mature and cardiac remodeling progresses. Follow-up assessments track continued cardiac function improvement.
Individual results vary. These timelines are based on clinical observations and are not guaranteed outcomes. Your specialist will provide personalized expectations during your consultation.
Hastaların Deneyimleri
StemCell Longevita İstanbul'da rejeneratif tıbbı tercih eden hastalardan gerçek sonuçlar
"Kardiyoloğum kalp fonksiyonundaki iyileşmenin yalnızca ilaçla ulaşılandan öte olduğunu söyledi. Üç yıldır ilk kez yeniden bahçe işleriyle uğraşıyorum."
"Rehabilitasyon ile rejeneratif tıbbın kombinasyonu beklenenden daha hızlı bir iyileşme sağladı. İstanbul kaderimi değiştirdi."
Your Cardiovascular Treatment Journey
our approach protocol is designed and administered by specialists trained in both the United States and Turkey, ensuring the highest standards of cardiovascular care.
Step 01: Cardiac Assessment
Our cardiologist reviews your medical history, echocardiography results, and diagnostic tests to evaluate your condition.
Step 02: Free Phone Consultation
Once approved, we present treatment options and pricing with a complimentary consultation to address your questions.
Step 03: Stem Cell Preparation
After deposit, we prepare umbilical cord-derived MSCs in our GMP-certified laboratory, typically taking 5–10 days.
Step 04: Treatment Administration
Free transportation to our Istanbul clinic where the specialist administers your intravenous stem cell infusion.
Step 05: Follow-Up Monitoring
Our specialist monitors your cardiac markers and functional improvement according to a scheduled follow-up plan.
Expert Cardiac Care
Board-Certified Specialists
Our cardiovascular treatment team includes specialists with extensive experience in regenerative cardiology. Each care plan is individually tailored based on your specific cardiac condition, ensuring optimal outcomes.
Watch Our Patient Stories & Expert Insights
See real results and hear from our medical team about stem cell therapy treatments, procedures, and patient outcomes.
Tüm Rejeneratif Tıp Uygulamaları
Çeşitli durumlar için kapsamlı rejeneratif tıp uygulamalarımızı keşfedin. Daha fazla bilgi için herhangi bir seçeneğe tıklayın.
İlgili Tedaviler
İlgili Makaleler
İlgili tedaviler ve terapiler hakkında derinlemesine araştırma makalelerimizi ve rehberlerimizi keşfedin.
Kalp Hastalığı: Kardiyak Rejenerasyona Kök Hücre Yaklaşımları
Çeşitli kardiyovasküler durumları olan hastalarda doku onarımını teşvik ederek ve kardiyak fonksiyonu iyileştirerek rejeneratif tıp yaklaşımlarınin kalp sağlığını nasıl destekleyebileceğini anlayın.
Makaleyi Okuİnme Gelişmesi: Kök Hücreler Nörolojik Gelişmeyi Nasıl Destekler
İnme rehabilitasyonunda rejeneratif tıp yaklaşımlarınin potansiyelini, etki mekanizmalarını ve motor ve bilişsel fonksiyonda bildirilen gelişmeleri keşfedin.
Makaleyi OkuRejeneratif tıp yaklaşımlarıni Anlamak: Kapsamlı Bir Rehber
Rejeneratif tıp yaklaşımlarınin bilimi, türleri, uygulamaları ve günümüzün sağlık hizmetlerinde rejeneratif tıbbın potansiyeli hakkında derin bir bakış.
Makaleyi OkuDünya Çapında Bu Tedavi Ne Kadar Tutar?
StemCell Longevita'daki bu rejeneratif tıp maliyetlerini diğer ülkelerdeki kliniklerle karşılaştırın.
| Ülke | Tipik Maliyet |
|---|---|
| United States | $20,000 – $40,000 |
| United Kingdom | £15,000 – £30,000 |
| Germany | €18,000 – €35,000 |
| South Korea | $15,000 – $28,000 |
| StemCell Longevita (Turkey) | €8,950'den Başlayan |
Fiyatlar, göbek kordonu kaynaklı mezenkimal kök hücre (MSC) tedavileri sunan karşılaştırılabilir kök hücre kliniklerinin piyasa araştırmasına dayanmaktadır (2025-2026). Gerçek fiyatlar klinik, hücre sayısı ve duruma göre değişiklik gösterir.
Detailed guides for this condition: